REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID)

Not Applicable

Recruiting

• Conditions: Asthma, Bronchial; Primary indication of asthma; D001249

• Registration Number: JPRN-jRCT1030210488
• Lead Sponsor: Clinical Trials Administrator

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-12-17
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

A patient must meet the following criteria to be eligible for inclusion in the study:
1. Male or female, 12 years or older at the baseline visit
2. Initiating treatment with DUPIXENT for a primary indication of asthma according to the country-specific prescribing information
3. Willing and able to comply with the required clinic visits, study procedures and assessments
4. Able to understand and complete study-related questionnaires
5. Provide signed informed consent; for patients under the age of 18, both parental (legal guardian) consent and patient assent are required

Exclusion Criteria

A patient who meets any of the following criteria will be excluded from the study
1. Patients who have a contraindication to DUPIXENT according to the country-specific prescribing information
2. Treatment with dupilumab within 6 months before the screening visit, or within 6 months of the baseline visit if the screening and baseline occur on the same day
3. Any condition that, in the opinion of the investigator, may interfere with ability of the patient to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other medical, social, or personal conditions and circumstances that can predictably prevent the patient from adequately completing the schedule of visits and assessments.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-Assessment of patient demographics (eg, gender, age, and race)<br>-Assessment of patient baseline characteristics (eg, prior medications and procedures,<br>medical history, asthma history, weight, height)

Secondary Outcome Measures

Name	Time	Method
-Descriptive summaries of DUPIXENT and other asthma treatments used during the study, including doses and dose frequency, treatment duration, asthma treatment<br>associations (eg, DUPIXENT monotherapy, DUPIXENT + ICS, DUPIXENT + ICS + additional controllers), and reasons for initiation and for discontinuation/switching<br>-Time course of clinical outcome parameters - patient reported outcomes (PROs) - for asthma and relevant comorbidities<br>-Descriptive summary of adverse events (AEs) reported in the study